MedTrace Logo

To Explore Cognitive Neural Mechanism of Autoimmune Encephalitis by Using Neuropsychological Tests and Multi-modal MRI

NCT03530462 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 22

Last updated 2018-05-21

No results posted yet for this study

Summary

Most of patients with autoimmune encephalitis are left with permanent cognitive deficits of varying severity. The patients' life and career would be affected definitely by cognitive deficits. Recently, more and more clinical physician have begun to focus on cognitive impairment of patients with autoimmune encephalitis. Generally, the outcome was measured by the modified Rankin Scale (mRS). However, the mRS are commonly used to evaluate the degree of disability or dependence in the daily activities of the patients suffering from a stroke and cognition function were minimally evaluated in this scale. It is crucial to adopt detailed cognition tools to study the long-term cognitive outcomes and as an indicator of overall curative effect judgment in autoimmune encephalitis.

Currently, only early immunotherapy is uniformly and consistently considered to produce favorable cognitive outcomes. However, studies concerning the association of second-line immunotherapy with cognitive outcomes have been scarce and have shown conflicting results regarding autoimmune encephalitis.

Hence, the goal of this study was to explore cognitive neural mechanism of autoimmune encephalitis by using neuropsychological tests and multi-mode MRIs.

Conditions

Interventions

DRUG

rituximab

375 mg/m2 weekly for 4 weeks

DRUG

cyclophosphamide

750 mg/m2 monthly for 4-6 cycles depending on the response

DRUG

Steroids

500-1000 mg of methylprednisolone daily for 3 days, then tapered doses

DRUG

Intravenous immunoglobulin

intravenous immunoglobulin (IVIG) with or without plasmapheresis

Sponsors & Collaborators

  • First Affiliated Hospital of Zhejiang University

    lead OTHER

Principal Investigators

  • Benyan Luo, Ph.D · The First Affiliated Hospital, Zhejiang University

Eligibility

Min Age
16 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-04-07
Primary Completion
2018-02-28
Completion
2018-02-28

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03530462 on ClinicalTrials.gov